

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7967516

<b>SUBMISSION TYPE:</b>	RESUBMISSION
<b>NATURE OF CONVEYANCE:</b>	PATENT SECURITY AGREEMENT
<b>RESUBMIT DOCUMENT ID:</b>	507669462
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ADC THERAPEUTICS SA	08/15/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.
<b>Street Address:</b>	399 PARK AVENUE, 38TH FLOOR
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10022
<b>PROPERTY NUMBERS Total: 4</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16819185
<b>Application Number:</b>	17812950
<b>Application Number:</b>	18056082
<b>Application Number:</b>	18056080
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	IPDOCKET@LW.COM, KRISTIN.AZCONA@LW.COM
<b>Correspondent Name:</b>	LATHAM & WATKINS LLP
<b>Address Line 1:</b>	650 TOWN CENTER DRIVE, 20TH FL
<b>Address Line 4:</b>	COSTA MESA, CALIFORNIA 92626
<b>ATTORNEY DOCKET NUMBER:</b>	058516-0144
<b>NAME OF SUBMITTER:</b>	KRISTIN J AZCONA
<b>SIGNATURE:</b>	/KJA/
<b>DATE SIGNED:</b>	05/23/2023
<b>Total Attachments: 10</b>	
source=ADCT - Patent Security Agreement (Executed)#page1.tif	
source=ADCT - Patent Security Agreement (Executed)#page2.tif	

source=ADCT - Patent Security Agreement (Executed)#page3.tif  
source=ADCT - Patent Security Agreement (Executed)#page4.tif  
source=ADCT - Patent Security Agreement (Executed)#page5.tif  
source=ADCT - Patent Security Agreement (Executed)#page6.tif  
source=ADCT - Patent Security Agreement (Executed)#page7.tif  
source=ADCT - Patent Security Agreement (Executed)#page8.tif  
source=ADCT - Patent Security Agreement (Executed)#page9.tif  
source=ADCT - Patent Security Agreement (Executed)#page10.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this “Agreement”) is made as of August 15, 2022, by ADC THERAPEUTICS SA (“Grantor”), in favor of OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P., as agent for the Secured Parties (as defined in the Loan Agreement referenced below) (in such capacity, together with its successors and assigns in such capacity, “Grantee”):

WITNESSETH

WHEREAS, ADC Therapeutics SA, a company formed under the laws of Switzerland (“Borrower”), the other Loan Parties from time to time party thereto, the Lenders from time to time party thereto and Grantee have entered into that certain Loan and Guaranty, dated as of August 15, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower; and

WHEREAS, pursuant to the terms of that certain Security Agreement dated as of August 15, 2022, by and among Grantee, Borrower and the other “Grantors” (as defined therein) from time to time party thereto (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), Grantor has granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon the Intellectual Property Collateral (as defined in the Loan Agreement), including all Patents (as defined in the Loan Agreement) therein, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations (as defined in the Loan Agreement), in each case other than Excluded Assets (as defined in the Loan Agreement).

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1. Incorporation of Loan Agreement and Security Agreement. The provisions of Sections 11.9, 11.10, 11.11 and 11.20 (with respect to Governing Law; Venue and Jurisdiction; Waiver of Jury Trial; and Service of Process) of the Loan Agreement are incorporated herein by reference thereto *mutatis mutandis*. Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Security Agreement, or if not defined therein, in the Loan Agreement. In the event of a conflict between a provision of the Security Agreement and a provision of this Agreement, the provision of the Security Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment of the Secured Obligations (including any Yield Protection Premium and Exit Charge), Grantor grants to Grantee, for the benefit of the Secured Parties, and hereby reaffirms its prior grant pursuant to the Security Agreement of, a continuing Lien on and security interest in Grantor’s entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “Patent Collateral”), whether now owned or existing or hereafter created, acquired or arising:

(a) all of the Patents included in the Intellectual Property Collateral, together with all proceeds with respect to the foregoing, including, without limitation, each Patent listed on Schedule A annexed hereto; and

(b) all income, royalties, damages and payments at any time due or payable or asserted under and with respect to the foregoing, including (i) damages payable with respect to any claim by Grantor against third parties for past, present or future infringement of each such Patent and (ii) all proceeds with respect to the foregoing.

Notwithstanding the foregoing, no Patent Collateral shall include (i) any Excluded Assets or (ii) any Collateral which is subject to any of the Swiss Security Documents or English Security Documents (in each case, as defined in the Loan Agreement).

3. Release. Section 11.24 of the Loan Agreement is incorporated herein and shall apply hereto *mutatis mutandis*.

4. Counterparts. This Agreement may be executed in several counterparts, and by each party on separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement or any other Loan Document by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof. The words "execution," "execute", "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement, the other Loan Documents and the transactions contemplated hereby and thereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

*[Signature Page Follows]*

IN WITNESS WHEREOF, Grantor has duly executed this Agreement as of the date first written above.

**ADC THERAPEUTICS SA**

*Ameet Mallik*

By: Ameet Mallik (Aug 12, 2022 11:28 EDT)

Name: Ameet Mallik

Title: Chief Executive Officer

Agreed and accepted as of  
the date first written above:

**OWL ROCK OPPORTUNISTIC MASTER FUND  
I, L.P.**, as Grantee

By: Owl Rock Opportunistic GP, LLC  
its General Partner

By: mmeha  
Name: Meenal Mehta  
Title: Authorized Signatory

**SCHEDULE A**

Grantor	ADCT Ref	Applicants	Title	General Status	Application Number	Filing Date	Granted Right Number	Grant Date	Jurisdiction
ADC Therapeutics SA	PAT002-US-CON	MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Pending	16/987348	11 Oct 2013			US
ADC Therapeutics SA	PAT002-US-NIP	MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	14/434818	11 Oct 2013	10736903	11 Aug 2020	US
ADC Therapeutics SA	PAT004-US-CON	MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-CD19 ANTIBODY CONJUGATES	Granted	15/897835	11 Oct 2013	10780181	22 Sep 2020	US
ADC Therapeutics SA	PAT004-US-CON2	MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-CD19 ANTIBODY CONJUGATES	Pending	16/934319	11 Oct 2013			US
ADC Therapeutics SA	PAT004-US-NIP	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-CD19 ANTIBODY CONJUGATES	Granted	14/434816	11 Oct 2013	9931414	03 Apr 2018	US
ADC Therapeutics SA	PAT006-US-CON	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE - ANTI-CD25 ANTIBODY CONJUGATES	Granted	15/911592	11 Oct 2013	10799596	13 Oct 2020	US
ADC Therapeutics SA	PAT006-US-CON2	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE - ANTI-CD25 ANTIBODY CONJUGATES	Pending	16/997862	11 Oct 2013			US
ADC Therapeutics SA	PAT006-US-NIP	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE - ANTI-CD25	Granted	14/434823	11 Oct 2013	9931415	03 Apr 2018	US

				ANTIBODY CONJUGATES									
ADC Therapeutics SA	PAT007-US- NP	MedImmune Limited	PYRROLOBENZODIA ZEPINE - ANTI-CD25 ANTIBODY CONJUGATES - SIMULLECT	Granted	14/434821	11 Oct 2013	10695433	30 Jun 2020	US				
ADC Therapeutics SA	PAT009-US- CON	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Pending	16/883139	11 Oct 2013			US				
ADC Therapeutics SA	PAT009-US- DIV	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	15/884665	11 Oct 2013	10722594	28 Jul 2020	US				
ADC Therapeutics SA	PAT009-US- NP	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	14/434826	11 Oct 2013	9919056	20 Mar 2018	US				
ADC Therapeutics SA	PAT015-US- NP	MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Granted	15/028589	10 Oct 2014	9950078	24 Apr 2018	US				
ADC Therapeutics SA	PAT017-US- NP	MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Granted	15/028591	10 Oct 2014	9956299	01 May 2018	US				
ADC Therapeutics SA	PAT025-US- CON	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Pending	17/006681	25 Nov 2015			US				
ADC Therapeutics SA	PAT025-US- NP	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Granted	15/529622	25 Nov 2015	10780096	22 Sep 2020	US				
ADC Therapeutics SA	PAT031-US- CON	ADC Therapeutics SA, MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	16/684222	15 Apr 2016			US				



ADC Therapeutics SA	PAT045-US-CON	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Pending	16/806910	25 Nov 2015			US
ADC Therapeutics SA	PAT055-US-DIV	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Pending	17/484467	08 Feb 2018			US
ADC Therapeutics SA	PAT055-US-NP	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Granted	16/484328	08 Feb 2018	11160872	02 Nov 2021	US
ADC Therapeutics SA	PAT056-US-NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY	Pending	16/605701	20 Apr 2018			US
ADC Therapeutics SA	PAT064-US-NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE	Pending	16/605708	20 Apr 2018			US
ADC Therapeutics SA	PAT087-US-CON	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Granted	16/197891	20 Apr 2018	10544223	28 Jan 2020	US
ADC Therapeutics SA	PAT087-US-NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	16/605692	20 Apr 2018			US
ADC Therapeutics SA	PAT096-US-NP	ADC Therapeutics SA, MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	16/622663	14 Jun 2018			US
ADC Therapeutics SA	PAT097-US-CON	ADC Therapeutics SA, MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION	Pending	17/699065	18 Mar 2022			US

			OF AN ANTI-CD19 ADC						
ADC Therapeutics SA	PAT1097-US-NP	ADC Therapeutics SA, MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Granted	16/622649	14 Jun 2018	11318211	03 May 2022	US
ADC Therapeutics SA	PAT1101-US-NP	ADC Therapeutics SA, MedImmune Limited	TREATMENT OF CAR T-CELL TOXICITY	Pending	16/968143	08 Feb 2019			US
ADC Therapeutics SA	PAT1102-US-NP	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE - ANTI-DLKI/KAAGI/MESOT HELIN ANTIBODY CONJUGATES - SYNAFIX	Pending	16/484313	08 Feb 2018			US
ADC Therapeutics SA	PAT1106-US-NP	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE RESISTANCE	Pending	17/414622	18 Dec 2019			US
ADC Therapeutics SA	PAT1109-US-NP	ADC Therapeutics SA, MedImmune Limited	MOLECULAR ADJUVANT	Pending	17/057486	22 May 2019			US
ADC Therapeutics SA	PAT114-US-NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY	Pending	17/259466	08 Jul 2019			US
ADC Therapeutics SA	PAT116-US-NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY	Pending	17/271108	30 Aug 2019			US
ADC Therapeutics SA	PAT120-US-NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY COMPRISING AN ANTI-CD25 ANTIBODY DRUG CONJUGATE AND A FURTHER AGENT	Pending	17/617864	08 Jun 2020			US
ADC Therapeutics SA	PAT123-US-NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG	Pending	17/617875	08 Jun 2020			US

			CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT						
ADC Therapeutics SA	PAT129-US- CON	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES	Pending	17/380859	04 Jun 2020			US
ADC Therapeutics SA	PAT132-US- NP	ADC Therapeutics SA, MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-PPBD DRUG CONJUGATE AND RADIOTHERAPY	Pending	PCT/EP2020/08 1361	06 Nov 2020			US
ADC Therapeutics SA	PAT134-US	ADC Therapeutics SA	ANTI-IL13R $\alpha$ 2 ANTIBODIES	Pending	17/389582	30 Jul 2021			US
ADC Therapeutics SA	PAT136-US	ADC Therapeutics SA, MedImmune Limited	PYRROLOBENZODIA ZEPINE-ANTIBODY CONJUGATES AND USES THEREOF	Pending	17/481918	22 Sep 2021			US
ADC Therapeutics SA	PAT201-US- NP	ADC Therapeutics SA	POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Granted	12/305648	22 Jun 2007	8216582	10 Jul 2012	US
ADC Therapeutics SA	PAT202-US- DIV	ADC Therapeutics SA	ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Granted	13/187424	03 Nov 2009	8580257	12 Nov 2013	US
ADC Therapeutics SA	PAT202-US- NP	ADC Therapeutics SA	ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Granted	13/127439	03 Nov 2009	9855291	02 Jan 2018	US

ADC Therapeutics SA	PAT203-US-CON	ADC Therapeutics SA	ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Granted	14/558186	28 Mar 2012	9393302	19 Jul 2016	US
ADC Therapeutics SA	PAT203-US-CON2	ADC Therapeutics SA	ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Granted	15/137368	28 Mar 2012	9828426	28 Nov 2017	US
ADC Therapeutics SA	PAT203-US-CON3	ADC Therapeutics SA	ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Granted	15/811545	28 Mar 2012	10597450	24 Mar 2020	US
ADC Therapeutics SA	PAT203-US-NP	ADC Therapeutics SA	ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Granted	14/036204	28 Mar 2012	8937163	20 Jan 2015	US
ADC Therapeutics SA	PAT204-US-CON	ADC Therapeutics SA	AGENTS FOR TREATING TRIPLE NEGATIVE BREAST CANCER	Granted	16/164656	09 Jan 2013	11084872	10 Aug 2021	US

PATENT

REEL: 063738 FRAME: 0012

RECORDED: 12/28/2022